Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Published extended data from the phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting MS in the peer reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official ...
finanzen12 天
EQS-News: Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Published extended data from the phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting MS in the peer reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official ...
Pharmaceutical Technology14 天
Brequinar by Clear Creek Bio for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Brequinar is under clinical development by Clear Creek Bio and currently in Phase II for Coronavirus Disease 2019 (COVID-19).